Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v2.4.0.6
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 6 Months Ended
Jan. 31, 2012
Jan. 31, 2011
Jan. 31, 2012
Jan. 31, 2011
Revenues:        
Clinical laboratory services $ 14,123 $ 12,278 $ 28,310 $ 24,668
Product revenues 9,542 10,237 19,245 20,421
Royalty and license fee income 1,308 1,219 3,170 4,297
Total revenues 24,973 23,734 50,725 49,386
Operating expenses:        
Cost of clinical laboratory services 8,709 7,492 17,523 15,065
Cost of product revenues 4,685 5,911 9,822 10,516
Research and development 1,703 2,021 3,328 3,778
Selling, general, and administrative 11,487 11,540 23,872 22,572
Provision for uncollectible accounts receivable 1,169 957 2,455 2,032
Legal 1,023 1,377 1,892 2,073
Total operating expenses 28,776 29,298 58,892 56,036
Operating loss (3,803) (5,564) (8,167) (6,650)
Other income (expense):        
Interest 14 4 12 9
Other 65 62 76 76
Foreign currency loss (352) (64) (323) (56)
Loss before income taxes (4,076) (5,562) (8,402) (6,621)
Provision for income taxes (145) (146) (313) (212)
Net loss $ (4,221) $ (5,708) $ (8,715) $ (6,833)
Net loss per common share:        
Basic and diluted (in Dollars per share) $ (0.11) $ (0.15) $ (0.23) $ (0.18)
Weighted average common shares outstanding:        
Basic and diluted (in Shares) 38,616 38,198 38,607 38,179